Rezolute, Inc. Profile Avatar - Palmy Investing

Rezolute, Inc.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibod…

Biotechnology
US, Redwood City [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Rezolute, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of RZLT's Analysis
CIK: 1509261 CUSIP: 76200L309 ISIN: US76200L3096 LEI: - UEI: -
Secondary Listings
RZLT has no secondary listings inside our databases.